Allopurinol and Pathogenesis of Cirrhosis

Phase 1

Completed

• Conditions: Cirrhoses, Liver
• Interventions: Drug: Placebo; Drug: Allopurinol Tablet

• Registration Number: NCT07033533
• Lead Sponsor: Tanta University

Brief Summary

Hepatic decompensation is a common healthcare issue

. This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-01
• Primary Completion: 2024-03-01
• Study Completion: 2024-03-01
• Status Verified: 2025-06
• Study First Submitted: 2025-06-14
• Study First Submitted QC: 2025-06-14
• Last Update Submitted: 2025-06-14
• Study First Posted: 2025-06-24
• Last Update Posted: 2025-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• age 18-75 both sex

Exclusion Criteria

• active GIT bleeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	Placebo	placebo
allopurinol	Allopurinol Tablet	-

Primary Outcome Measures

Name	Time	Method
biomarkers as zonulin, LPS, MMP-13, MDA	6 MONTHS

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, Egypt